Antiviral Treatment of Coronavirus Disease-2019 Pneumonia

Link to article at PubMed

Clin Chest Med. 2023 Jun;44(2):279-297. doi: 10.1016/j.ccm.2022.11.008. Epub 2022 Nov 28.


Direct acting antivirals and monoclonal antibodies reduce morbidity and mortality associated with severe acute respiratory syndrome coronavirus 2 infection. Persons at higher risk for disease progression and hospitalized patients with coronavirus disease-2019 (COVID-19) benefit most from available therapies. Following an emphasis on inpatient treatment of COVID-19 during the early pandemic, several therapeutic options were developed for outpatients with COVID-19. Additional clinical trials and real-world studies are needed to keep pace with the evolving pandemic.

PMID:37085220 | PMC:PMC9701636 | DOI:10.1016/j.ccm.2022.11.008

Leave a Reply

Your email address will not be published. Required fields are marked *